Adial Pharmaceuticals Stock Market Value
| ADIL Stock | USD 0.23 0.01 4.55% |
| Symbol | Adial |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Adial Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Adial Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Adial Pharmaceuticals.
| 10/25/2025 |
| 01/23/2026 |
If you would invest 0.00 in Adial Pharmaceuticals on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding Adial Pharmaceuticals or generate 0.0% return on investment in Adial Pharmaceuticals over 90 days. Adial Pharmaceuticals is related to or competes with Neurosense Therapeutics, Acurx Pharmaceuticals, Matinas BioPharma, Brainstorm Cell, Aprea Therapeutics, HCW Biologics, and Kiora Pharmaceuticals. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Adial Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Adial Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Adial Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 16.67 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.56 |
Adial Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adial Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Adial Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Adial Pharmaceuticals historical prices to predict the future Adial Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (1.10) | |||
| Treynor Ratio | (0.42) |
Adial Pharmaceuticals January 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.41) | |||
| Mean Deviation | 2.89 | |||
| Coefficient Of Variation | (629.81) | |||
| Standard Deviation | 3.81 | |||
| Variance | 14.51 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (1.10) | |||
| Treynor Ratio | (0.42) | |||
| Maximum Drawdown | 16.67 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.56 | |||
| Skewness | 0.1112 | |||
| Kurtosis | 0.2047 |
Adial Pharmaceuticals Backtested Returns
Adial Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.17, which signifies that the company had a -0.17 % return per unit of risk over the last 3 months. Adial Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Adial Pharmaceuticals' Mean Deviation of 2.89, standard deviation of 3.81, and Risk Adjusted Performance of (0.11) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.47, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Adial Pharmaceuticals will likely underperform. At this point, Adial Pharmaceuticals has a negative expected return of -0.67%. Please make sure to confirm Adial Pharmaceuticals' treynor ratio and the relationship between the skewness and period momentum indicator , to decide if Adial Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.81 |
Very good predictability
Adial Pharmaceuticals has very good predictability. Overlapping area represents the amount of predictability between Adial Pharmaceuticals time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Adial Pharmaceuticals price movement. The serial correlation of 0.81 indicates that around 81.0% of current Adial Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.81 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Adial Pharmaceuticals Correlation, Adial Pharmaceuticals Volatility and Adial Pharmaceuticals Alpha and Beta module to complement your research on Adial Pharmaceuticals. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Adial Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.